Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/26217
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | - |
dc.contributor.author | SILVA-FILHO, Carlos R. | - |
dc.contributor.author | BARBOSA, Ricardo Antonio G. | - |
dc.contributor.author | SILVA- JR., Carlindo V. | - |
dc.contributor.author | MALBOUISSON, Luiz M. S. | - |
dc.contributor.author | CARMONA, Maria Jose C. | - |
dc.contributor.author | JORGE-SANTOS, Silvia Regina C. | - |
dc.date.accessioned | 2018-05-08T14:29:25Z | - |
dc.date.available | 2018-05-08T14:29:25Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | CLINICS, v.73, 2018 | - |
dc.identifier.issn | 1807-5932 | - |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/26217 | - |
dc.description.abstract | OBJECTIVES: The objective of this study was to apply a pharmacokinetics-pharmacodynamics approach to investigate the free propofol plasma levels in patients undergoing coronary artery bypass grafting under hypothermic conditions compared with the off-pump procedure. METHODS: Nineteen patients scheduled for on-pump coronary artery bypass grafting under hypothermic conditions (n=10) or the equivalent off-pump surgery (n=9) were anesthetized with sufentanil and propofol target-controlled infusion (2 mg/mL) during surgery. The propofol concentration was then reduced to 1 mu g/mL, and a pharmacokinetics-pharmacodynamics analysis using the maximum-effect-sigmoid model obtained by plotting the bispectral index values against the free propofol plasma levels was performed. RESULTS: Significant increases (two-to five-fold) in the free propofol plasma levels were observed in the patients subjected to coronary artery bypass grafting under hypothermic conditions. The pharmacokinetics of propofol varied according to the free drug levels in the hypothermic on-pump group versus the off-pump group. After hypothermic coronary artery bypass was initiated, the distribution volume increased, and the distribution half-life was prolonged. Propofol target-controlled infusion was discontinued when orotracheal extubation was indicated, and the time to patient extubation was significantly higher in the hypothermic on-pump group than in the off-pump group (459 versus 273 min, p=0.0048). CONCLUSIONS: The orotracheal intubation time was significantly longer in the hypothermic on-pump group than in the off-pump group. Additionally, residual hypnosis was identified through the pharmacokinetics-pharmacodynamics approach based on decreases in drug plasma protein binding in the hypothermic on-pump group, which could explain the increased hypnosis observed with this drug in this group of patients. | - |
dc.language.iso | eng | - |
dc.publisher | HOSPITAL CLINICAS, UNIV SAO PAULO | - |
dc.relation.ispartof | Clinics | - |
dc.rights | openAccess | - |
dc.subject | Coronary Artery Bypass | - |
dc.subject | Cardiopulmonary Bypass | - |
dc.subject | Propofol | - |
dc.subject | Protein Binding | - |
dc.subject | Pharmacokinetics | - |
dc.subject | Pharmacodynamics | - |
dc.subject.other | performance liquid-chromatography | - |
dc.subject.other | controlled infusion | - |
dc.subject.other | cardiac-surgery | - |
dc.subject.other | protein-binding | - |
dc.subject.other | parameter sets | - |
dc.subject.other | drug | - |
dc.subject.other | fraction | - |
dc.title | Application of a pharmacokinetics-pharmacodynamics approach to the free propofol plasma levels during coronary artery bypass grafting surgery with hypothermic cardiopulmonary bypass | - |
dc.type | article | - |
dc.rights.holder | Copyright HOSPITAL CLINICAS, UNIV SAO PAULO | - |
dc.identifier.doi | 10.6061/clinics/2018/e178 | - |
dc.identifier.pmid | 29451620 | - |
dc.subject.wos | Medicine, General & Internal | - |
dc.type.category | original article | - |
dc.type.version | publishedVersion | - |
hcfmusp.author.external | SILVA-FILHO, Carlos R.:Univ Sao Paulo, Fac Ciencias Farmaceut, Sao Paulo, SP, Brazil | - |
hcfmusp.author.external | SILVA- JR., Carlindo V.:Univ Sao Paulo, Fac Ciencias Farmaceut, Sao Paulo, SP, Brazil | - |
hcfmusp.author.external | JORGE-SANTOS, Silvia Regina C.:Univ Sao Paulo, Fac Ciencias Farmaceut, Sao Paulo, SP, Brazil | - |
hcfmusp.description.volume | 73 | - |
hcfmusp.origem | WOS | - |
hcfmusp.origem.id | WOS:000425353700001 | - |
hcfmusp.origem.id | 2-s2.0-85042375634 | - |
hcfmusp.origem.id | SCIELO:S1807-59322018000100202 | - |
hcfmusp.publisher.city | SAO PAULO | - |
hcfmusp.publisher.country | BRAZIL | - |
hcfmusp.relation.reference | Barbosa RAG, 2009, CLINICS, V64, P215, DOI 10.1590/S1807-59322009000300012 | - |
hcfmusp.relation.reference | Bienert A, 2011, ARZNEIMITTEL-FORSCH, V61, P545, DOI 10.1055/s-0031-1300552 | - |
hcfmusp.relation.reference | COETZEE JF, 1995, ANESTHESIOLOGY, V82, P1328, DOI 10.1097/00000542-199506000-00003 | - |
hcfmusp.relation.reference | Dawidowicz AL, 2006, CHEM-BIOL INTERACT, V159, P149, DOI 10.1016/j.cbi.2005.10.108 | - |
hcfmusp.relation.reference | Dawidowicz AL, 2008, EUR J PHARM SCI, V34, P30, DOI 10.1016/j.ejps.2008.02.004 | - |
hcfmusp.relation.reference | Filho CRDS, 2007, LAT AM J PHARM, V26, P748 | - |
hcfmusp.relation.reference | Hiraoka H, 2004, CLIN PHARMACOL THER, V75, P324, DOI 10.1016/j.clpt.2003.12.004 | - |
hcfmusp.relation.reference | Jeleazcov C, 2012, BRIT J ANAESTH, V109, P698, DOI 10.1093/bja/aes253 | - |
hcfmusp.relation.reference | Kalitynski R, 2006, ACTA PHARMACOL SIN, V27, P1637, DOI 10.1111/j.1745-7254.2006.00454.x | - |
hcfmusp.relation.reference | MARSH B, 1991, BRIT J ANAESTH, V67, P41, DOI 10.1093/bja/67.1.41 | - |
hcfmusp.relation.reference | Mazoit JX, 1999, BRIT J CLIN PHARMACO, V47, P35, DOI 10.1046/j.1365-2125.1999.00860.x | - |
hcfmusp.relation.reference | Peeters MMM, 2008, CLIN PHARMACOL THER, V83, P443, DOI 10.1038/sj.clpt.6100309 | - |
hcfmusp.relation.reference | Takizawa E, 2006, BRIT J ANAESTH, V96, P179, DOI 10.1093/bja/aei293 | - |
hcfmusp.relation.reference | Tang J, 2011, ANAESTHESIST, V60, P835, DOI 10.1007/s00101-011-1907-y | - |
hcfmusp.relation.reference | Tsubokawa T, 2013, J ANESTH, V27, P346, DOI 10.1007/s00540-012-1524-1 | - |
hcfmusp.relation.reference | Vree TB, 1999, J CHROMATOGR B, V721, P217, DOI 10.1016/S0378-4347(98)00466-6 | - |
hcfmusp.relation.reference | VUYK J, 1995, ANESTH ANALG, V81, P1275, DOI 10.1097/00000539-199512000-00026 | - |
hcfmusp.relation.reference | Wiczling P, 2012, PHARMACOL REP, V64, P113, DOI 10.1016/S1734-1140(12)70737-5 | - |
hcfmusp.relation.reference | Yoshitani K, 2003, BRIT J ANAESTH, V90, P122, DOI 10.1093/bja/aeg010 | - |
dc.description.index | MEDLINE | - |
dc.identifier.eissn | 1980-5322 | - |
hcfmusp.citation.scopus | 1 | - |
hcfmusp.scopus.lastupdate | 2024-04-12 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MCG Artigos e Materiais de Revistas Científicas - HC/ICHC Artigos e Materiais de Revistas Científicas - HC/InCor Artigos e Materiais de Revistas Científicas - HC/InRad Artigos e Materiais de Revistas Científicas - LIM/08 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_SILVA-FILHO_Application_of_a_pharmacokineticspharmacodynamics_approach_to_the_free_2018.PDF | 367.2 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.